Sökning: WFRF:(Hochman Judith S.)
> (2017) >
Inflammatory Biomar...
Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease : Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial
-
- Held, Claes, 1956- (författare)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi
-
- White, Harvey D. (författare)
- Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand.
-
- Stewart, Ralph A. H. (författare)
- Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand.
-
visa fler...
-
- Budaj, Andrzej (författare)
- Grochowski Hosp, Postgrad Med Sch, Warsaw, Poland.
-
- Cannon, Christopher P. (författare)
- Brigham & Womens Hosp, Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA.
-
- Hochman, Judith S. (författare)
- NYU, Dept Med, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA.
-
- Koenig, Wolfgang (författare)
- Univ Ulm, Med Ctr, Dept Internal Med Cardiol 2, Ulm, Germany.;Tech Univ Munich, Deutsch Herzzentrum Munchen, Munich, Germany.;DZHK German Ctr Cardiovasc Res, Partner Site Munich Heart Alliance, Munich, Germany.
-
- Siegbahn, Agneta, 1947- (författare)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Klinisk kemi
-
- Steg, Philippe Gabriel (författare)
- Hop Bichat Claude Bernard, AP HP, Dept Hosp Univ FIRE, Paris, France.;Paris Diderot Univ, Sorbonne Paris Cite, Paris, France.;NHLI Imperial Coll, Royal Brompton Hosp, ICMS, London, England.;INSERM, FACT, U1148, Paris, France.
-
- Soffer, Joseph (författare)
- GlaxoSmithKline, Metab Pathways & Cardiovasc Therapeut Area, Collegeville, PA USA.
-
- Weaver, Douglas (författare)
- Henry Ford Heart & Vasc Inst, Detroit, MI USA.
-
- Östlund, Ollie (författare)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)
-
- Wallentin, Lars, 1943- (författare)
- Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)
-
visa färre...
-
(creator_code:org_t)
- 2017
- 2017
- Engelska.
-
Ingår i: Journal of the American Heart Association. - 2047-9980. ; 6:10
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BackgroundEvaluation of cardiovascular prognosis in patients with stable coronary heart disease is based on clinical characteristics and biomarkers indicating dysglycemia, dyslipidemia, renal dysfunction, and possibly cardiac dysfunction. Inflammation plays a key role in atherosclerosis, but the association between inflammatory biomarkers and clinical outcomes is less studied in this population.Methods and ResultsOverall, 15 828 patients with coronary heart disease in the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial werer and randomized to treatment with darapladib or placebo and observed for a median of 3.7 years. In 14 611 patients, levels of interleukin-6 (IL-6) and high-sensitivity C-reactive protein were measured in plasma samples: median levels were2.1 (interquartile range, 1.4-3.2) ng/Land1.3 (interquartile range, 0.6-3.1) mg/L, respectively. Associations between continuous levels or quartile groups and adjudicated outcomes were evaluated by spline graphs and Cox regression adjusted for clinical factors and cardiovascular biomarkers. IL-6 was associated with increased risk of major adverse cardiovascular events (quartile 4 versus quartile 1 hazard ratio [HR], 1.60; 95% confidence interval [CI], 1.30-1.97; P< 0.0001); cardiovascular death (HR, 2.15; 95% CI, 1.53-3.04; P< 0.0001); myocardial infarction (HR, 1.53; 95% CI, 1.14-2.04; P< 0.05); all-cause mortality (HR, 2.11; 95% CI, 1.62-2.76; P< 0.0001); and risk of hospitalization for heart failure (HR, 2.28; 95% CI, 1.34-3.89; P< 0.001). Cancer death was doubled in the highest IL-6 quartile group (HR, 2.34; 95% CI, 1.20-4.53; P< 0.05). High-sensitivity C-reactive protein was associated with both cardiovascular and non-cardiovascular events in the unadjusted model, but these did not remain after multivariable adjustments.ConclusionsIL-6, an upstream inflammatory marker, was independently associated with the risk of major adverse cardiovascular events, cardiovascular and all-cause mortality, myocardial infarction, heart failure, and cancer mortality in patients with stable coronary heart disease. IL-6 might reflect a pathophysiological process involved in the development of these events.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- coronary disease
- C-reactive protein
- inflammation
- interleukin-6
- white blood cells
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Held, Claes, 195 ...
-
White, Harvey D.
-
Stewart, Ralph A ...
-
Budaj, Andrzej
-
Cannon, Christop ...
-
Hochman, Judith ...
-
visa fler...
-
Koenig, Wolfgang
-
Siegbahn, Agneta ...
-
Steg, Philippe G ...
-
Soffer, Joseph
-
Weaver, Douglas
-
Östlund, Ollie
-
Wallentin, Lars, ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
Journal of the A ...
- Av lärosätet
-
Uppsala universitet